Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **vaginal microbiota** refers to the complex microbial community inhabiting the vagina, where **Lactobacillus species**, including *Lactobacillus acidophilus*, are key dominant members in healthy women—comprising up to 95% in optimal states. These bacteria play crucial roles by producing lactic acid that maintains low pH (<4.5), creating an environment hostile to many pathogens. *Lactobacillus* also produces hydrogen peroxide and antimicrobial peptides that further suppress harmful microbes. Colonization with beneficial lactobacilli is associated with reduced risk for bacterial vaginosis and other infections due to both direct inhibition through competitive exclusion at epithelial surfaces and indirect effects via modulation of host immune responses—including downregulation of proinflammatory cytokines. The ability to adhere effectively is mediated by surface proteins such as S-layer protein A (SlpA) in *L. acidophilus*, which are essential for stable colonization. Disruption or loss of these protective communities can lead to increased susceptibility to infection and inflammation. **Note:** "Vaginal microbiota via Lactobacillus acidophilus colonization" is not a canonical molecular target like a receptor or enzyme but rather describes an ecological state/process involving microbial populations within the vagina—specifically emphasizing beneficial colonization by *Lactobacillus* spp., including *L. acidophilus*. Therefore, it does not fit standard definitions used for drug targets such as receptors or enzymes; instead it represents a therapeutic strategy/goal rather than a discrete molecular entity. > “This report provides experimental evidence supporting the concept that the vaginal microflora regulates epithelial innate immunity...and that topically applied microbicides may alter both bacterial and epithelial components...” > “There are many microbial colonizations in the vagina...among which Lactobacillus plays a major role...can produce lactic acid...acidify the vaginal environment...and inhibit growth...” > “An important mechanism for protection from BV recurrence is vaginal acidity, which is largely a function of lactic-acid production by lactobacilli.”
For probiotics targeting this ecosystem or using L. acidophilus as an active agent: Competitive exclusion/colonization resistance against pathogens by occupying adhesion sites on the epithelium; Acidification via lactic acid production to inhibit pathogen growth; Induction/modulation of host innate immunity and anti-inflammatory cytokines.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Vaginal microbiota (Lactobacillus acidophilus colonization).